Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00883896
Other study ID # 3199K1-2001
Secondary ID B19810012008-006
Status Completed
Phase Phase 2
First received
Last updated
Start date June 18, 2009
Est. completion date February 18, 2011

Study information

Verified date September 2022
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.


Recruitment information / eligibility

Status Completed
Enrollment 195
Est. completion date February 18, 2011
Est. primary completion date February 18, 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening - Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h - Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit. Exclusion Criteria: - Subjects with other rheumatic diseases - Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer) - Any prior use of B cell-depleting therapy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Placebo
Part 1: Placebo SC administration every 2 weeks X 10 weeks.
Drug:
ILV-094
Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
ILV-094
Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
Other:
Placebo
Part 2: Placebo SC administration every 2 weeks X 10 weeks
Drug:
ILV-094
Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks

Locations

Country Name City State
Belgium AZ Jan Palfijn Antwerpen
Belgium Cliniques Universitaires St Luc Avenue Hippocrate 10 UCL Brussels
Belgium Universitair Ziekenhuis Gent Gent
Belgium Reuma Instituut Hasselt
Belgium Chu Liege Sart Tilman B 35 Liege
Colombia Centro de Reumatologia y Ortopedia Barranquilla Atlantico
Colombia Fundacion Instituto de Reumatologia Fernando Chalem Bogota Cundinamarca
Colombia Medicity S.A.S Bucaramanga Santander
Colombia Servimed EU Bucaramanga Santander
Croatia University Hospital Centre Rijeka Rijeka
Croatia University Hospital Center Zagreb Zagreb
Germany Klinikum Innenstadt der Ludwig-Maximillians-Universität München
Hungary Budai Irgalmasrendi Hospital Budapest
Hungary Obudai Egeszsegugyi Centrum Kft Budapest
Hungary Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft. Nyiregyhaza
Hungary Markusovszky Hospital Szombathely
Japan Inoue Hospital Gunma
Japan Matsubara Clinic Hyogo
Japan Matsubara Mayflower Hospital Hyogo
Japan Medical Corporation Wakoukai Kurashiki Kousai Hospital Kurashiki Okayama
Japan Gunma University Hospital Maebashi Gunma
Japan National Hospital Organization Sagamihara National Hospital Sagamihara Kanagawa
Japan Institute of Rheumatology, Tokyo Women's Medical University Hospital Shinjyuku-ku Tokyo
Japan National Hospital Organization Shimoshizu National Hospital Yotsukaidou Chiba
Mexico Centro de Estudio de Investigacion Basica y Clinica S.C Jalisco Guadalajara
Netherlands AMC Amsterdam Noord-Holland
Romania Centrul de Boli Reumatismale Dr. I. Stoia Bucuresti
Romania SC Duo Medical SRL Bucuresti
Romania Spitalul Clinic Colentina Bucuresti
Romania Spitalul Clinic Sf. Maria Bucuresti
Romania Centrul Medical Terra Med Cluj-Napoca Cluj
Romania Spitalul Clinic Judetean de Urgenta Tg Mures Targu Mures
Russian Federation Municipal Institution City Clinical Hospital #40 Ekaterinburg
Russian Federation City Clinical Hospital # 1 n.a. Pirogov Moscow
Russian Federation Institute of Rheumatology of Russian academy of Medical Scie Moscow
Russian Federation State Educational Institution of Additional Professional Education Saint Petersburg
Russian Federation State Health care institution of Leningrad Regional Clinical Hospital Saint Petersburg
Russian Federation State education institution of higher vocational education Smolensk State Medical Academy Roszdrav Smolensk
Russian Federation State Healthcare Institution Yaroslavl Regional Clinical Hospital Yaroslavl
United States Deaconess Hospital Cincinnati Ohio
United States Arthritis Care and Diagnostic Center Dallas Texas
United States Altoona Center for Clinical Research Duncansville Pennsylvania
United States Arizona Arthritis & Rheumatology Research, PLLC Glendale Arizona
United States Diagnostic Rheumatology and Research PC Indianapolis Indiana
United States Desert Medical Advances Palm Desert California
United States Arthritis Center Palm Harbor Florida
United States Clayton Medical Research Saint Louis Missouri
United States Arthritis & Osteoporosis Center of South Texas San Antonio Texas
United States Clinical Research Advantage, Inc. Sarasota Florida
United States The Arthritis Specialty Centre Sarasota Florida
United States Clinical Research Center of Reading West Reading Pennsylvania
United States Clinical Research Center of Reading, LLC Wyomissing Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Belgium,  Colombia,  Croatia,  Germany,  Hungary,  Japan,  Mexico,  Netherlands,  Romania,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12 ACR20 response: greater than or equal to (>=) 20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP). Week 12
Secondary Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 2, 4, 6, 8 and 10 ACR20 response: >=20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP). Week 2, 4, 6, 8, 10
Secondary Percentage of Participants With an American College of Rheumatology 50 Percent (ACR50) Response at Week 2, 4, 6, 8, 10 and 12 ACR50 response: >=50 percent improvement in tender joint count; >=50 percent improvement in swollen joint count; and 50 improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP). Week 2, 4, 6, 8, 10, 12
Secondary Percentage of Participants With an American College of Rheumatology 70 Percent (ACR70) Response at Week 2, 4, 6, 8, 10 and 12 ACR70 response:>=70 percent improvement in tender joint count; >=70 percent improvement in swollen joint count; and 70 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP). Week 2, 4, 6, 8, 10, 12
Secondary Disease Activity Score Based on 28-Joints Count (DAS28) Using C-Reactive Protein (CRP) DAS28 (CRP) was calculated from number of swollen joints and tender joints using the 28 joints count; CRP (milligram/Liter [mg/L]); and general health visual analog scale (VAS) score (participant rated scale with scores ranging from 0mm [very well] to 100mm [extremely bad]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 (CRP) less than or equal to (<=) 3.2 implied low disease activity, greater than (>) 3.2 to 5.1 implied moderate to high disease activity, and less than (<) 2.6 implied remission. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Disease Activity Score Based on 28-Joints Count (DAS28) Using Erythrocyte Sedimentation Rate (ESR) DAS28 (ESR) was calculated from the number of swollen joints and tender joints using the 28 joints count; ESR (millimeters per hour [mm/hour]); and general health VAS score (participant rated scale with scores ranging from 0 [very well] to 100 [extremely bad]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and <2.6 implied remission. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Tender Joints Counts (TJC) Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Swollen Joints Count (SJC) Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Physician Global Assessment of Disease Activity Physician global assessment of disease activity was measured on an 11-point scale, ranging from 0 to 10, where 0 = no disease activity and 10 = extreme disease activity. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Participant Global Assessment of Disease Activity Participants answered: "considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a scale ranging from 0 to 10, where 0 = no disease activity and 10 = extreme disease activity. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Pain Visual Analog Scale (VAS) Participants assessed the amount of pain currently experienced by them on a 100 millimeter (mm) VAS ranging from 0= no pain to 100= severe pain. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary General Health Visual Analog Scale (VAS) General health VAS is a 100 mm line marked by the participant. Participants were asked, "In general how would you rate your health currently concerning the arthritis?" Scores ranged from 0 mm = very well to 100 mm = extremely bad. Baseline, Week 2, 4, 6, 8, 10, 12
Secondary Health Assessment Questionnaire-Disability Index (HAQ-DI) Score Health assessment questionnaire-disability index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to perform activity. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Baseline, Week 4, 2, 6, 8, 10, 12
Secondary 36-Item Short-Form Health Survey (SF-36) SF-36 is a standardized survey consisting of 36 items summarized into 8 multi-item scales evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality and mental health. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) derived are derived by aggregating the 8 aspects. The score for each aspect and physical and mental component summary are scaled 0-100 where, higher score indicating highest level of functioning. Baseline, Week 4, 8, 12
Secondary Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale FACIT-fatigue is a 13-item questionnaire. Participants score each item on a 5-point scale ranging from 0 (not at all) to 4 (very much). The scoring algorithm is such that the item responses are reversed in score (except for 2 items, "I have energy" and "I am able to do my usual activities"), in order to reflect higher scores as less fatigue. The sum of all responses resulted in the FACIT-fatigue total score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. Baseline, Week 4, 8, 12
Secondary Number of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28 DAS28-based EULAR response criteria was used to measure individual response as none, good and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Week 2, 4, 6, 8, 10, 12
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4